Imunon Offloads Written-Off ThermoDox Asset for Equity, Up to $16.5M in Milestones
IMNN is trading near its 52-week low of $0.96 (0.1% above the low).
Summary
Imunon is selling the ThermoDox rights it had already written off to VoxelDox, taking a roughly 4.76% equity stake plus up to $16.5M in milestones and 3.5%-6% royalties on net sales. No cash changes hands up front, and the deal only closes if VoxelDox completes a planned $2.5M financing, so near-term value is essentially zero. As part of the arrangement, Imunon may appoint one VoxelDox director and one non-voting observer. The point is focus: with $6.9M in cash, a going concern warning and a dilutive ATM already in use, management is clearing a legacy asset off the books and putting everything behind the Phase 3 OVATION 3 trial of IMNN-001 in ovarian cancer. The upside here is optionality on a GBM program that still needs funding, not a balance-sheet fix. Watch whether VoxelDox closes its $2.5M raise, and OVATION 3 enrollment and data as the real value driver.
At the time of this announcement, IMNN was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.96 to $5.20. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.